These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 31288820)

  • 21. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
    le Roux CW; Astrup A; Fujioka K; Greenway F; Lau DCW; Van Gaal L; Ortiz RV; Wilding JPH; Skjøth TV; Manning LS; Pi-Sunyer X;
    Lancet; 2017 Apr; 389(10077):1399-1409. PubMed ID: 28237263
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
    Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
    Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: the EMPACEF study.
    Gaborit B; Ancel P; Abdullah AE; Maurice F; Abdesselam I; Calen A; Soghomonian A; Houssays M; Varlet I; Eisinger M; Lasbleiz A; Peiretti F; Bornet CE; Lefur Y; Pini L; Rapacchi S; Bernard M; Resseguier N; Darmon P; Kober F; Dutour A
    Cardiovasc Diabetol; 2021 Mar; 20(1):57. PubMed ID: 33648515
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of liraglutide on cardiac function in patients with type 2 diabetes mellitus: randomized placebo-controlled trial.
    Bizino MB; Jazet IM; Westenberg JJM; van Eyk HJ; Paiman EHM; Smit JWA; Lamb HJ
    Cardiovasc Diabetol; 2019 Apr; 18(1):55. PubMed ID: 31039778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
    Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
    Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
    Tanaka K; Okada Y; Tokutsu A; Tanaka Y
    Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liraglutide treatment for the prevention of glucose tolerance deterioration in women with prior gestational diabetes mellitus: A 52-week randomized controlled clinical trial.
    Foghsgaard S; Vedtofte L; Andersen ES; Bahne E; Andreasen C; Sørensen AL; Forman JL; Mathiesen ER; Svare JA; Clausen TD; Damm P; Holst JJ; Knop FK; Vilsbøll T
    Diabetes Obes Metab; 2024 Jan; 26(1):201-214. PubMed ID: 37846555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
    Sorli C; Harashima SI; Tsoukas GM; Unger J; Karsbøl JD; Hansen T; Bain SC
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):251-260. PubMed ID: 28110911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial.
    Ludvik B; Frías JP; Tinahones FJ; Wainstein J; Jiang H; Robertson KE; García-Pérez LE; Woodward DB; Milicevic Z
    Lancet Diabetes Endocrinol; 2018 May; 6(5):370-381. PubMed ID: 29483060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue.
    Jendle J; Nauck MA; Matthews DR; Frid A; Hermansen K; Düring M; Zdravkovic M; Strauss BJ; Garber AJ;
    Diabetes Obes Metab; 2009 Dec; 11(12):1163-72. PubMed ID: 19930006
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss.
    Ghanim H; Batra M; Green K; Abuaysheh S; Hejna J; Makdissi A; Borowski R; Kuhadiya ND; Chaudhuri A; Dandona P
    Diabetes Obes Metab; 2020 Oct; 22(10):1742-1752. PubMed ID: 32424935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride.
    Jendle J; Hyötyläinen T; Orešič M; Nyström T
    Cardiovasc Diabetol; 2021 Dec; 20(1):237. PubMed ID: 34920733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial.
    Feig DS; Donovan LE; Zinman B; Sanchez JJ; Asztalos E; Ryan EA; Fantus IG; Hutton E; Armson AB; Lipscombe LL; Simmons D; Barrett JFR; Karanicolas PJ; Tobin S; McIntyre HD; Tian SY; Tomlinson G; Murphy KE;
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):834-844. PubMed ID: 32946820
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
    Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
    Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of liraglutide on glycemic endpoints in people of Western European and South Asian descent with T2DM using multiple daily insulin injections: results of the MAGNA VICTORIA studies.
    Bizino MB; Jazet IM; van Eyk HJ; Rensen PCN; Geelhoed-Duijvestijn PH; Kharagjitsingh AV; Paiman EHM; Smit JW; Lamb HJ
    Acta Diabetol; 2021 Apr; 58(4):485-493. PubMed ID: 33399989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.
    Zang L; Liu Y; Geng J; Luo Y; Bian F; Lv X; Yang J; Liu J; Peng Y; Li Y; Sun Y; Bosch-Traberg H; Mu Y
    Diabetes Obes Metab; 2016 Aug; 18(8):803-11. PubMed ID: 27060930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liraglutide reverses pronounced insulin-associated weight gain, improves glycaemic control and decreases insulin dose in patients with type 2 diabetes: a 26 week, randomised clinical trial (ELEGANT).
    de Wit HM; Vervoort GM; Jansen HJ; de Grauw WJ; de Galan BE; Tack CJ
    Diabetologia; 2014 Sep; 57(9):1812-9. PubMed ID: 24947583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.